Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Axogen reported second-quarter 2026 financial results on July 29, 2026.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Axogen reported second-quarter 2026 financial results on July 29, 2026
- Detailed revenue, profitability, guidance, and operating metrics are contained in furnished Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Second-quarter 2026 financial results presentation posted July 29, 2026
- Updated corporate presentation highlights materials management may use with analysts and investors
- Investors should review Exhibits 99.2 and 99.3 for detailed financial and strategic information
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $69.7M, up 23.1% YoY; growth exceeded 50% in Breast, but product mix reduced gross margin to 72.7% from 74.2%
- GAAP net loss $1.5M versus $0.6M income; adjusted net income $7.3M, while adjusted EBITDA fell to $8.4M from $9.3M
- Full-year revenue guidance raised to at least $279M, representing at least 24% growth; gross margin target remains at least 73%
- Balance sheet strengthened with $113.4M in cash, restricted cash, and investments; debt was eliminated following $48.6M repayment
- Six-month free cash flow turned positive at $4.1M versus negative $7.2M; clinical studies and Trace Biosciences investment support longer-term adoption potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.